RXFP3 Receptor Antibodies

RXFP3 (relaxin family peptide receptor 3) is a G protein–coupled receptor (GPCR) that primarily binds relaxin-3 (RLN3), a neuropeptide involved in stress, arousal, and metabolic regulation. Pharmacologically, RXFP3 predominantly couples to Gi/o proteins, leading to inhibition of adenylate cyclase, reduced cyclic AMP (cAMP) levels, and activation of downstream signaling pathways such as MAPK/ERK and PI3K/Akt. RXFP3 is highly expressed in the brain, particularly in regions including the hypothalamus, amygdala, hippocampus, and brainstem, with limited expression in peripheral tissues. Functionally, RXFP3 signaling modulates a variety of neuroendocrine, behavioral, and autonomic processes, including feeding behavior, stress responses, arousal, learning and memory, and emotional regulation. Activation of RXFP3 generally produces anxiolytic, orexigenic, and stress-buffering effects, depending on the neural circuit involved. The receptor’s distribution and signaling properties suggest it plays a central role in integrating homeostatic and behavioral responses to stress and energy balance. Because of these functions, RXFP3 is being explored as a potential therapeutic target for disorders such as anxiety, depression, obesity, and addiction. Overall, RXFP3 serves as a critical node in the relaxin-3 neuropeptide system regulating mood, motivation, and metabolic state. For more information on RXFP3 pharmacology please refer to the IUPHAR database.